Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

• 主要な著者: Letian Song (著者), Shenghua Gao (著者), Bing Ye (著者), Mianling Yang (著者), Yusen Cheng (著者), Dongwei Kang (著者), Fan Yi (著者), Jin-Peng Sun (著者), Luis Menéndez-Arias (著者), Johan Neyts (著者), Xinyong Liu (著者), Peng Zhan (著者)
• フォーマット: 図書
• 出版事項: Elsevier, 2024-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The main protease (Mpro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle. The covalent Mpro inhibitor nirmatrelvir (in combination with ritonavir, a pharmacokinetic enhancer) and the non-covalent inhibitor ensitrelvir ha...